Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
News|Articles|May 7, 2024
Taking Data Into Real World Practice
Author(s)Carmen Kosicek, MSN, PMHNP-BC
You no longer have to trade physical health for mental health.
Advertisement
"You no longer have to trade physical health for mental health."
Carmen Kosicek, MSN, PMHNP-BC, joined Psychiatric Times at the 2024 American Psychiatric Association Annual Meeting to discuss the applicability of learned principles in psychiatry and the importance of psychiatric nurse practitioners and physician assistants. How do you use currently available medications? Why do you choose one treatment over another?
Ms Kosicek is the CEO, Founder, and and a practicing PMHNP at Visionary Psychiatry—a hybrid, onsite/remote, psychiatric specialty of medication management providers offering services throughout Oregon.
Advertisement
Related to this article
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5